|
Market Closed -
Nasdaq
16:00:00 2026-10-26 EDT
|
5-day change | 1st Jan Change | ||
| 6.470 USD | -0.46% |
|
+2.86% | -46.71% |
| 10-23 | Ocular Therapeutix, Inc. - Special Call | |
| 10-20 | Ocular Therapeutix Has 75% Success Probability for Axpaxli in Wet Age-Related Macular Degeneration, UBS Says | MT |
Company Valuation: Ocular Therapeutix, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 534 | 216.4 | 491.6 | 1,343 | 2,586 | 1,421 | - | - |
| Change | - | -59.47% | 127.16% | 173.13% | 92.64% | -45.06% | - | - |
| Enterprise Value (EV) 1 | 421.2 | 168.1 | 491.6 | 1,019 | 2,586 | 995.8 | 1,196 | 1,140 |
| Change | - | -60.09% | 192.42% | 107.3% | 153.81% | -61.5% | 20.12% | -4.7% |
| P/E | -77.4x | -2.9x | -4.42x | -7x | -8.55x | -4.34x | -4.58x | -6.06x |
| PBR | - | - | - | - | - | 3.75x | 4.71x | 3.92x |
| PEG | - | -0x | -1.07x | -0.3x | -0.5x | -0.86x | 0.87x | 0.2x |
| Capitalization / Revenue | 12.3x | 4.2x | 8.41x | 21.1x | 49.8x | 26.9x | 13.9x | 5.12x |
| EV / Revenue | 9.68x | 3.26x | 8.41x | 16x | 49.8x | 18.8x | 11.7x | 4.11x |
| EV / EBITDA | -5.57x | -2.2x | -6.19x | -6.07x | -9.73x | -3.3x | -3.4x | -3.87x |
| EV / EBIT | -5.4x | -2.14x | -5.97x | -5.93x | -9.58x | -2.87x | -3.53x | -4.06x |
| EV / FCF | -6.31x | -2.65x | -6.44x | -7.49x | -11.9x | -3.57x | -5.11x | -27.8x |
| FCF Yield | -15.8% | -37.7% | -15.5% | -13.3% | -8.39% | -28% | -19.6% | -3.6% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.09 | -0.97 | -1.01 | -1.22 | -1.42 | -1.492 | -1.413 | -1.068 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 43.52 | 51.49 | 58.44 | 63.72 | 51.95 | 52.84 | 102 | 277.4 |
| EBITDA 1 | -75.62 | -76.54 | -79.4 | -168 | -265.7 | -301.7 | -351.7 | -294.9 |
| EBIT 1 | -78.04 | -78.65 | -82.38 | -171.8 | -270 | -346.4 | -339.2 | -280.8 |
| Net income 1 | -6.553 | -71.04 | -80.74 | -193.5 | -265.9 | -334.2 | -330.4 | -275.7 |
| Net Debt 1 | -112.7 | -48.29 | - | -323.6 | - | -425.1 | -224.7 | -280.9 |
| Reference price 2 | 6.970 | 2.810 | 4.460 | 8.540 | 12.140 | 6.470 | 6.470 | 6.470 |
| Nbr of stocks (in thousands) | 76,610 | 77,010 | 110,219 | 157,217 | 213,047 | 219,616 | - | - |
| Announcement Date | 2/28/22 | 3/6/23 | 3/11/24 | 3/3/25 | 2/5/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.34x | 18.85x | -3.3x | -.--% | 1.42B | |
| 37.58x | 13.15x | 27.92x | 0.53% | 1,140B | |
| 38.98x | 6.55x | 18.43x | 2% | 641B | |
| 37.5x | 8.41x | 17.39x | 2.4% | 507B | |
| 21.33x | 5.19x | 12.91x | 2.53% | 383B | |
| 102.5x | 5.75x | 24.67x | 2.42% | 347B | |
| 21.61x | 5.64x | 13.85x | 2.84% | 293B | |
| 22.44x | 4.53x | 12.94x | 1.95% | 266B | |
| 28.21x | 7.23x | 12.94x | 2.27% | 240B | |
| -46.25x | 7.08x | 27.47x | 2.08% | 197B | |
| Average | 25.95x | 8.24x | 16.52x | 1.9% | 401.52B | |
| Weighted average by Cap. | 35.00x | 8.33x | 20.42x | 1.8% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- OCUL Stock
- Valuation Ocular Therapeutix, Inc.
Select your edition
All financial news and data tailored to specific country editions
